Schedule 13D ownership disclosure

AXOVANT SCIENCES LTD

Security class unavailable · CUSIP: G0750W104

Event date: 2016-10-18

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
75,000,000
Percent of class
75.6000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-16-150925
Form type
SC 13D
Filer
Sio Gene Therapies Inc.
CIK
CIK 1636050
Filed
Oct 19, 2016
Reporting period
Oct 18, 2016
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub